During the last session, eFFECTOR Therapeutics Inc. (NASDAQ:EFTR)’s traded shares were 0.14 million. At the end of the trading day, the stock’s price was $0.82, reflecting an intraday gain of 0.75% or $0.01. The 52-week high for the EFTR share is $40.42, that puts it down -4829.27 from that peak though still a striking 8.54% gain since the share price plummeted to a 52-week low of $0.75. The company’s market capitalization is $37.11M, and the average intraday trading volume over the past 10 days was 0.12 million shares, and the average trade volume was 76.73K shares over the past three months.
eFFECTOR Therapeutics Inc. (EFTR) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.20. EFTR has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.16.
eFFECTOR Therapeutics Inc. (NASDAQ:EFTR) trade information
eFFECTOR Therapeutics Inc. (EFTR) registered a 0.75% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.75% in intraday trading to $0.82 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 1.40%, and it has moved by -41.35% in 30 days. Based on these gigs, the overall price performance for the year is -91.69%. The short interest in eFFECTOR Therapeutics Inc. (NASDAQ:EFTR) is 94000.0 shares and it means that shorts have 1.36 day(s) to cover.
The consensus price target of analysts on Wall Street is $18.68, which implies an increase of 95.61% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.40 and $50.00 respectively. As a result, EFTR is trading at a discount of -5997.56% off the target high and -314.63% off the low.
eFFECTOR Therapeutics Inc. (EFTR) estimates and forecasts
Statistics show that eFFECTOR Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. eFFECTOR Therapeutics Inc. (EFTR) shares have gone down -84.27% during the last six months, with a year-to-date growth rate less than the industry average at -218.18% against 1.00. In the rating firms’ projections, revenue will decrease -2.10% compared to the previous financial year.
Revenue for the current quarter is expected to be $520k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $420k by the end of Sep 2022.
While earnings are projected to return -327.30% in 2022.
eFFECTOR Therapeutics Inc. is due to release its next quarterly earnings on November 08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
eFFECTOR Therapeutics Inc. (NASDAQ:EFTR)’s Major holders
eFFECTOR Therapeutics Inc. insiders own 18.26% of total outstanding shares while institutional holders control 71.65%, with the float percentage being 87.66%. SR One Capital Management, LP is the largest shareholder of the company, while 24 institutions own stock in it. As of Mar 30, 2022, the company held over 6.82 million shares (or 16.48% of all shares), a total value of $27.36 million in shares.
The next largest institutional holding, with 4.82 million shares, is of Abingworth, LLP’s that is approximately 11.65% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $19.34 million.
Also, the Mutual Funds coming in first place with the largest holdings of eFFECTOR Therapeutics Inc. (EFTR) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 0.38 million shares. This amounts to just over 0.92 percent of the company’s overall shares, with a $1.53 million market value. The same data shows that the other fund manager holds slightly less at 0.12 million, or about 0.28% of the stock, which is worth about $0.47 million.